The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.

@article{Arrieta2015TheIO,
  title={The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.},
  author={Oscar Arrieta and Andr{\'e}s F Cardona and Luis Corrales and Alma Delia Campos-Parra and Roberto S{\'a}nchez-Reyes and Eduardo Amieva-Rivera and July Rodr{\'i}guez and Carlos F Vargas and Hern{\'a}n Carranza and Jorge Otero and Nikki Karachaliou and Horacio Astudillo and Rafael Rosell},
  journal={Lung cancer},
  year={2015},
  volume={87 2},
  pages={169-75}
}
OBJECTIVES In non-small cell lung cancer (NSCLC), the association between common EGFR mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been well established. However, this has not been investigated for rare EGFR mutations or their impact on treatment response and outcome to EGFR TKIs (primary objective) and chemotherapy… CONTINUE READING